Dr. Hofmeister Discusses Sequencing Treatment in Myeloma

Craig Hofmeister, MD
Published: Tuesday, Oct 31, 2017



Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.

At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.
 


Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.

At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x